Leire Escudero-Ibarz

TL;DR: The activating nature of the RRAGC mutations, their existence in the dominant clone and their stability during disease progression support their potential as an excellent candidate for therapeutic targeting.

TL;DR: KLF2 mutation is the most common genetic change in SMZL and identifies a subset with a distinct genotype characterised by multi-genetic changes that may deregulate various signalling pathways and generate cooperative oncogenic properties, thereby contributing to lymphomagenesis.

TL;DR: A significant association is shown between biased usage of autoreactive IGHV and somatic mutation of NF‐κB regulators in MALT lymphoma, arguing for their cooperation in sustaining chronic B‐cell receptor signalling and driving oncogenesis in lymphoma development.

TL;DR: A robust practical approach for high-throughput mutation screening using archival FFPE tissues is established and most false-positive variants were due to DNA degradation, deamination, and Taq polymerase errors, but they were nonreproducible and could be efficiently eliminated by duplicate experiments.

TL;DR: A20, encoded by TNFAIP3, is a molecular “brake” of the canonical NF-κB activation pathway and attenuates the NF-kB activity triggered by a number of surface receptors and possesses deubiquitinating activity.